Skip to main content
. Author manuscript; available in PMC: 2020 Aug 20.
Published in final edited form as: Endocr Relat Cancer. 2018 Jun 12;25(10):893–908. doi: 10.1530/ERC-18-0159

Fig. 1.

Fig. 1

Proposed mechanism of action of the mTORC1-inhibitor everolimus. Everolimus inhibits the mTORC1 complex and thereby down-regulates the mTORC1/p70S6K signaling cascade, preventing the cell from cell cycle progression, survival and proliferation. Inhibition of mTORC1/p70S6K leads to disinhibition/activation of IRS-1 and thereby activation of PI3K/Akt, which in turn inhibits GSK3 by phosphorylation.